Gedatolisib (Standard)

Gedatolisib (Standard) is the analytical standard of Gedatolisib. This product is intended for research and analytical applications. Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2].

Product Specifications

CAS Number

[1197160-78-3]

UNSPSC

12352100

Hazard Statement

H302, H315, H319, H335

Target

MTOR; PI3K; Reference Standards

Related Pathways

Others; PI3K/Akt/mTOR

Field of Research

Cancer

Purity

97.70

Smiles

CN(C1CCN(C(C2=CC=C(NC(NC3=CC=C(C4=NC(N5CCOCC5)=NC(N6CCOCC6)=N4)C=C3)=O)C=C2)=O)CC1)C

Molecular Formula

C32H41N9O4

Molecular Weight

615.73

Precautions

H302, H315, H319, H335

References & Citations

[1]Venkatesan AM, et al. Bis (morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010, 53 (6), 2636-2645.|[2]Freitag H, et al. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. Neuroendocrinology. 2017;105 (1) :90-104.